Katie Jorgensen is the site head of BaseCamp Waltham, ElevateBio’s flagship genetic medicine biomanufacturing facility. Since joining, she has been instrumental in accelerating the development and manufacturing of cell and gene therapies and strengthening partnerships with biotech and pharma innovators. Previously at the company, Jorgensen served as vice president, commercial operations and CMC program management.
Under Jorgensen’s leadership, ElevateBio has expanded its industry impact by consistently exceeding partner expectations. Her team has optimized end-to-end processes from development to manufacturing, significantly improving efficiency and enabling partners to achieve more in less time.
Jorgensen’s efforts have contributed to an impressive 98%-plus batch success rate across cell therapies, viral vectors and mRNA programs. Additionally, her leadership has contributed to multiple advancements for partner programs, including an accelerated timeline—by a year—to an investigational new drug application for a lead program. She has also reduced a manufacturing process timeframe for an investigational CAR T therapy, leading to getting important therapies to patients faster. Most recently, the site achieved certification for commercial readiness (Dark Horse Consulting), showcasing the maturation of systems and a focus on quality, scalability and manufacturing excellence.
Jorgensen’s leadership serves as a blueprint for ElevateBio’s new BaseCamp Pittsburgh facility, expected to be operational in 2027. She champions a culture of excellence and empowerment, particularly encouraging women leaders to drive continued innovation and meaningful impact.
Prior to ElevateBio, Jorgensen spent a decade at AbbVie, recently serving as director, manufacturing and tech transfer. She has a Master of Science in engineering management from Tufts University and a Bachelor of Science in biomedical engineering from the University of Connecticut.